SICENCE 新闻发布 作者：孟繁平 稿号：NRR-41-13单链可变区片段融合蛋白治疗重症肌无力单链可变区片段融合蛋白治疗重症肌无力单链可变区片段637是重症肌无力的抗原特异性单链可变区片段，能与人类肌肉乙酰胆碱受体亚基的67-76位氨基酸结合。中国延边大学孟繁平博士所带领的团队将单链可变区片段基因与人血清白蛋白相结合，并在毕赤酵母中表达两者的融合蛋白。结果发现该融合蛋白能与人体肋间肌神经肌肉接头中的乙酰胆碱受体结合，且其对重症肌无力患者血清与乙酰胆碱受体结合的抑制率为2.0-77.4%，同时其在正常血清中的稳定性约为3d。因此认为这种单链可变区片段-人血清白蛋白可以作为特异性免疫抑制治疗重症肌无力的可选制剂。相关文献发表于中国神经再生研究（英文版） 杂志2014年4月第8期。免疫组化染色 ScFv637-HAS 能够与人肋间肌中的 AChR 原位结合Article: “ Fusion protein of single-chain variable domain fragments for treatment of myasthenia gravis,“ by Fangfang Li, Fanping Meng, Quanxin Jin, Changyuan Sun, Yingxin Li, Honghua Li, Songzhu Jin (Department of Immunology and Pathogenic Biology, College of Medicine, Yanbian University, Yanji, Jilin Province, China)Li FF, Meng FP, Jin QX, Sun CY, Li YX, Li HH, Jin SZ. Fusion protein of single-chain variable domain fragments for treatment of myasthenia gravis. Neural Regen Res. 2014;9(8):851-856.欲获更多资讯：Neural Regen Res SICENCE 新闻发布 作者：孟繁平 稿号：NRR-41-13Fusion protein of single-chain variable domain fragments and myasthenia gravis Single-chain variable domain fragment (scFv) 637 is an antigen-specific scFv of myasthenia gravis and it can bind to acetylcholine receptor in the residues 67-76 of -subunit of acetylcholine receptor. Dr. Fanping Meng and his team, College of Medicine, Yanbian University in China conjugated scFv and human serum albumin genes and detected the fusion protein in Pichia pastoris. Results showed that the fusion protein bound to acetylcholine receptors in neuromuscular junction of human intercostal muscle and the inhibition rate of fusion protein binding to acetycholine receptor was 2.0-77.4%, and the stability of fusion protein in static healthy sera was about 3 days. This approach suggests that scFV-human serum albumin is a potential candidate for specific immunosuppressive therapy of myasthenia gravis. This paper was published in Neural Regeneration Research (Vol. 9, No. 8, 2014).Immunohistochemical staining revealed that single-chain variable domain fragment 637-human serum albumin can bind to acetylcholine receptor in situ at neuromuscular junctions of human intercostal muscle.Article: “ Fusion protein of single-chain variable domain fragments for treatment of myasthenia gravis,“ by Fangfang Li, Fanping Meng, Quanxin Jin, Changyuan Sun, Yingxin Li, Honghua Li, Songzhu Jin (Department of Immunology and Pathogenic Biology, College of Medicine, Yanbian University, Yanji, Jilin Province, China)Li FF, Meng FP, Jin QX, Sun CY, Li YX, Li HH, Jin SZ. Fusion protein of single-chain variable domain fragments for treatment of myasthenia gravis. Neural Regen Res. 2014;9(8):851-856.